CEREBRAL PALSY Strategies to accurately predict development of neurodevelopmental impairment in preterm neonates are limited. This cohort study assessed the relationship between neonatal movement and development of cerebral palsy at 2 years’ age, and found an association between absent fidgeting movements and CP development. While further study is necessary, General Movement Assessment is useful in identifying infants who may go on to develop CP.
Magnesium sulfate is commonly used antenatally in mothers at high risk of preterm delivery. This randomized controlled trial tested the effectiveness of antenatal magnesium sulfate administration to prevent cerebral palsy in neonates born at 24-31 weeks gestational age. The trial found that compared to placebo, magnesium sulfate treatment reduced the incidence of CP in preterm neonates at 2 years of age. While further study is necessary to streamline treatment recommendations and address effectiveness in preterm infants <24 weeks gestational age, magnesium sulfate is effective in reducing the incidence of cerebral palsy in preterm infants.